Ocwen Board of Directors Authorizes $50 Million Share Repurchase Program
OCWEN BOARD OF DIRECTORS AUTHORIZES $50 MILLION SHARE REPURCHASE[...]
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial[...]
01/19/2022 | Press release | Distributed by Public on 01/19/2022 00:11
Please select the service you want to use:
Copyright ©2006-2022 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact